text:
Insulin resistance
From Wikipedia, the free encyclopedia
Jump to: navigation, search
This article needs more medical references for verification or relies too heavily on primary sources. Please review the contents of the article and add the appropriate references if you can. Unsourced or poorly sourced material may be challenged and removed. (October 2015)
Insulin resistance
Classification and external resources
Specialty
Endocrinology
eMedicine
med/1173
MeSH
C18.452.394.968.500
[edit on Wikidata]
Insulin resistance (IR) is a pathological condition in which cells fail to respond normally to the hormone insulin. The body produces insulin when glucose starts to be released into the bloodstream from the digestion of carbohydrates in the diet. Normally this insulin response triggers glucose being taken into body cells, to be used for energy, and inhibits the body from using fat for energy. The concentration of glucose in the blood decreases as a result, staying within the normal range even when a large amount of carbohydrates is consumed. When the body produces insulin under conditions of insulin resistance, the cells are resistant to the insulin and are unable to use it as effectively, leading to high blood sugar. Beta cells in the pancreas subsequently increase their production of insulin, further contributing to a high blood insulin level. This often remains undetected and can contribute to the development of type 2 diabetes or latent autoimmune diabetes of adults.[1] Although this type of chronic insulin resistance is harmful, during acute illness it is actually a well-evolved protective mechanism. Recent investigations have revealed that insulin resistance helps to conserve the brain's glucose supply by preventing muscles from taking up excessive glucose.[2] In theory, insulin resistance should even be strengthened under harsh metabolic conditions such as pregnancy, during which the expanding fetal brain demands more glucose.
People who develop type 2 diabetes usually pass through earlier stages of insulin resistance and prediabetes, although those often go undiagnosed. Insulin resistance is a syndrome (a set of signs and symptoms) resulting from reduced insulin activity; it is also part of a larger constellation of symptoms called the metabolic syndrome.
Insulin resistance may also develop in patients who have recently experienced abdominal or bariatric procedures.[3] This acute form of insulin resistance that may result post-operatively tends to increase over the short term, with sensitivity to insulin typically returning to patients after about five days.[4]
Contents
[hide]
1 Signs and symptoms
2 Associated risk factors
3 Cause
3.1 Molecular mechanism
3.2 Diet
3.3 Sedentary lifestyle
3.4 Protease inhibitors
3.5 Cellular level
3.6 Molecular
3.7 Disease
3.8 HCV and insulin resistance
4 Pathophysiology
5 Diagnosis
5.1 Fasting insulin levels
5.2 Glucose tolerance testing (GTT)
5.3 Measuring insulin resistance
5.3.1 Hyperinsulinemic euglycemic clamp
5.3.2 Modified insulin suppression test
5.4 Alternatives
6 Management
7 History
8 See also
9 References
10 Further reading
11 External links
Signs and symptoms[edit]
These depend on poorly understood variations in individual biology and consequently may not be found with all people diagnosed with insulin resistance.[5]
Increased hunger
Lethargy (tiredness)
Brain fogginess and inability to focus
High blood sugar
Weight gain, fat storage, difficulty losing weight – for most people, excess weight is from high subcutaneous fat storage; the fat in IR is generally stored in and around abdominal organs in both males and females; it is currently suspected that hormones produced in that fat are a precipitating cause of insulin resistance
Increased blood cholesterol levels
Increased blood pressure; many people with hypertension are either diabetic or pre-diabetic and have elevated insulin levels due to insulin resistance; one of insulin's effects is to control arterial wall tension throughout the body
Associated risk factors[edit]
Several associated risk factors include the following:
Genetic factors (inherited component):
Family history of type 2 diabetes
Insulin receptor mutations (Donohue syndrome)
LMNA mutations (familial partial lipodystrophy)[citation needed][6][7]
Cultural variables, such as diet varying with race and class; factors related to stress, socio-economic status and history have been shown to activate the stress response, which increases the production of glucose and insulin resistance, as well as inhibiting pancreatic function and thus might be of importance,[8][9] although it is not fully corroborated by the scientific evidence.
Particular physiological conditions and environmental factors:
Age 40–45 years or older[8][9]
Obesity[8][9]
The tendency to store fat preferentially in the abdomen (also known as "abdominal obesity)", as opposed to storing it in hips and thighs[9]
Sedentary lifestyle, lack of physical exercise[8][9]
Hypertension[8]
High triglyceride level (hypertriglyceridemia)[8]
Low level of high-density lipoprotein (also known as HDL cholesterol or "good cholesterol")[8]
Prediabetes, blood glucose levels have been too high in the past, i.e. the patient's body has previously shown slight problems with its production and usage of insulin ("previous evidence of impaired glucose homeostasis")[8][9]
Having developed gestational diabetes during past pregnancies[8][9]
Giving birth to a baby weighing more than 9 pounds (a bit over 4 kilograms)[8][9]
Pathology:
Obesity and overweight (BMI > 25)
Metabolic syndrome (hyperlipidemia + HDL cholesterol level < 0.90 mmol/L or triglyceride level > 2.82 mmol/L), hypertension (> 140/90 mmHg), or arteriosclerosis
Liver pathologies
Infection (Hepatitis C[10])
Hemochromatosis
Gastroparesis
Polycystic ovary syndrome (PCOS)
Hypercortisolism (e.g., Cushing's syndrome, glucocorticoid therapy)[11]
Medications (e.g., glucosamine, rifampicin, isoniazid, olanzapine, risperidone, progestogens, glucocorticoids, methadone, many antiretrovirals)
Cause[edit]
Molecular mechanism[edit]
Insulin resistance implies that the body's cells (primarily muscle) lose sensitivity to insulin, a hormone secreted by the pancreas to promote glucose utilization. At the molecular level, a cell senses insulin through insulin receptors, with the signal propagating through a cascade of molecules collectively known as PI3K/Akt/mTOR signaling pathway.[12] Recent studies suggested that the pathway may operate as a bistable switch under physiologic conditions for certain types of cells, and insulin response may well be a threshold phenomenon.[2][12][13] The pathway's sensitivity to insulin may be blunted by many factors such as free fatty acids,[14] causing insulin resistance. From a broader perspective, however, sensitivity tuning (including sensitivity reduction) is a common practice for an organism to adapt to the changing environment or metabolic conditions.[15] Pregnancy, for example, is a prominent change of metabolic conditions, under which the mother has to reduce her muscles' insulin sensitivity to spare more glucose for the brains (the mother's brain and the fetal brain). This can be achieved through raising the response threshold (i.e., postponing the onset of sensitivity) by secreting placental growth factor to interfere with the interaction between insulin receptor substrate (IRS) and PI3K, which is the essence of the so-called adjustable threshold hypothesis of insulin resistance.[2]
Diet[edit]
It is well known that insulin resistance commonly coexists with obesity.[16] Dietary fat has long been implicated as a driver of insulin resistance. Studies on animals have observed significant insulin resistance in rats after just 3 weeks on a high-fat diet (59% fat, 20% carb.)[17] Large quantities of saturated, monounsaturated, and polyunsaturated omega-6 fats all appear to be harmful to rats to some degree, compared to large amounts of starch, but saturated fat appears to be the most effective at producing IR.[18] This is partly caused by direct effects of a high-fat diet on blood markers, but, more significantly, ad libitum high-fat diet has the tendency to result in caloric intake that is far in excess of animals' energy needs, resulting in rapid weight gain. In humans, statistical evidence is more equivocal. Being insensitive to insulin is still positively correlated with fat intake, and negatively correlated with dietary fiber intake,[19] but both these factors are also correlated with excess body weight.
The effect of dietary fat is largely or completely overridden if the high-fat diet is modified to contain nontrivial quantities (in excess of 5–10% of total fat intake) of polyunsaturated omega-3 fatty acids.[18][20][21] This protective effect is most established with regard to the so-called "marine long-chain omega-3 fatty acids", EPA and DHA, found in algae, krill and fish oil; evidence in favor of other omega-3 fatty acids, in particular, the most common vegetable-based omega-3 fatty acid, ALA, also exists,[22] but it is more limited; some studies find ALA effective only among people with insufficient long-chain omega-3 intake,[23] and some studies fail to find any effect at all[24] (ALA may be converted partially into EPA and DHA by the human body, but the conversion rate is thought to be 10% or less, depending on diet and gender). The effect is thought to explain relatively low incidence of IR, type 2 diabetes, and obesity in polar foragers such as Alaskan Eskimos consuming their ancestral diet (which is very high in fat, but contains substantial amounts of omega-3),[25][26] however, it is not strong enough to prevent IR in the typical modern Western diet. Unlike their omega-6 counterparts (which may be produced cheaply from a variety of sources, such as corn and soybeans), major sources of omega-3 fatty acids remain relatively rare and expensive. Consequently, the recommended average intake of omega-3 for adult men in the United States is only 1.6 grams/day, or less than 2% of total fat; currently, the average consumption of omega-3 in the United States is approximately 1.3 grams/day, almost all of it in the form of ALA; EPA and DHA contributed less than 0.1 grams/day.[27]
Elevated levels of free fatty acids and triglycerides in the blood stream and tissues have been found in many studies to contribute to diminished insulin sensitivity.[18][28][29][30] Triglyceride levels are driven by a variety of dietary factors. They are correlated with excess body weight.[31] They tend to rise due to overeating and fall during fat loss.[32] At constant energy intake, triglyceride levels are correlated positively with trans fat intake and strongly inversely correlated with omega-3 intake. High-carbohydrate, low-fat diets were found by many studies to result in elevated triglycerides,[33] in part due to higher production of VLDL from fructose and sucrose, and in part because increased carbohydrate intake tends to displace some omega-3 fatty acids from the diet.
Several recent authors have suggested that the intake of simple sugars, and particularly fructose, is also a factor that contributes to insulin resistance.[34][35] Fructose is metabolized by the liver into triglycerides, and, as mentioned above, tends to raise their levels in the blood stream. Therefore, it may contribute to insulin resistance through the same mechanisms as dietary fat. Just like fat, high levels of fructose and/or sucrose induce insulin resistance in rats,[36][37] and, just as with fat, this insulin resistance is ameliorated by fish oil supplementation.[38] One study observed that a low-fat diet high in simple sugars (but not in complex carbohydrates and starches) significantly stimulates fatty acid synthesis, primarily of the saturated fatty acid palmitate, therefore, paradoxically, resulting in the plasma fatty acid pattern that is similar to that produced by a high-saturated-fat diet.[39] It should be pointed out that virtually all evidence of deleterious effects of simple sugars so far is limited to their concentrated formulations and sweetened beverages. In particular, very little is known about the effects of simple sugars in whole fruits and vegetables. If anything, epidemiological studies suggest that their high consumption is associated with somewhat lower risk of IR and/or metabolic syndrome.[40][41]
Yet another proposed mechanism involves the phenomenon known as leptin resistance. Leptin is a hormone that regulates long-term energy balance in many mammals. An important role of leptin is long-term inhibition of appetite in response to formation of body fat. This mechanism is known to be disrupted in many obese individuals: even though their leptin levels are commonly elevated, this does not result in reduction of appetite and caloric intake.[42] Leptin resistance may be triggered in rats by ad libitum consumption of energy-dense, highly palatable foods over a period of several days.[43] Chronic consumption of fructose in rats ultimately results in leptin resistance (however, this has only been demonstrated in a diet in which fructose provided 60% of calories;[44] consumption by humans in a typical Western diet is much lower.) Once leptin signalling has been disrupted, the individual becomes prone to further overeating, weight gain, and insulin resistance.
As elevated blood glucose levels are the primary stimulus for insulin secretion and production, habitually excessive carbohydrate intake is another likely contributor. This serves as a major motivation behind the low-carb family of diets. Furthermore, carbohydrates are not equally absorbed (for example, the blood glucose level response to a fixed quantity of carbohydrates in baked potatoes is about twice the response to the same quantity of carbohydrates in pumpernickel bread). Integrated blood glucose response to a fixed quantity of carbohydrates in a meal is known as glycemic index (GI). Some diets are based on this concept, assuming that consumption of low-GI food is less likely to result in insulin resistance and obesity, however, small to moderate amounts of simple sugars (i.e., sucrose, fructose, and glucose) in the typical developed-world diet seem to not have a causative effect on the development of insulin resistance.[45]
Once established, insulin resistance would result in increased circulating levels of insulin. Since insulin is the primary hormonal signal for energy storage into fat cells, which tend to retain their sensitivity in the face of hepatic and skeletal muscle resistance, IR stimulates the formation of new fatty tissue and accelerates weight gain.[46]
Another possible explanation is that both insulin resistance and obesity often have the same cause, systematic overeating, which has the potential to lead to insulin resistance and obesity due to repeated administration of excess levels of glucose, which stimulate insulin secretion; excess levels of fructose, which raise triglyceride levels in the bloodstream; and fats, which may be absorbed easily by the adipose cells, and tend to end up as fatty tissue in a hypercaloric diet. Some scholars go as far as to claim that neither insulin resistance, nor obesity really are metabolic disorders per se, but simply adaptive responses to sustained caloric surplus, intended to protect bodily organs from lipotoxicity (unsafe levels of lipids in the bloodstream and tissues): "Obesity should therefore not be regarded as a pathology or disease, but rather as the normal, physiologic response to sustained caloric surplus… As a consequence of the high level of lipid accumulation in insulin target tissues including skeletal muscle and liver, it has been suggested that exclusion of glucose from lipid-laden cells is a compensatory defense against further accumulation of lipogenic substrate."[47]
Fast food meals typically possess several characteristics, all of which have independently been linked to IR: they are energy-dense, palatable, and cheap, increasing risk of overeating and leptin resistance; simultaneously, they are high in dietary fat and fructose, and low in omega-3 and fiber; and they usually have high glycemic indices. Consumption of fast food has been proposed as a fundamental factor behind the metabolic syndrome epidemic and all its constituents.[46]
An American study has shown that glucosamine (often prescribed for joint problems) may cause insulin resistance.[48] Other studies, however, could not confirm a significant effect on blood glucose or insulin resistance.[49][50][51]
Studies show that high levels of cortisol within the bloodstream from the digestion of animal protein may contribute to the development of insulin resistance.[52][53] Several studies conclude that high uric acid levels, apart from other contributing factors, by itself may be a significant cause of insulin resistance.[54]
Vitamin D deficiency also is associated with insulin resistance.[55]
Sedentary lifestyle[edit]
Sedentary lifestyle increases the likelihood of development of insulin resistance.[56][57] It has been estimated that each 500 kcal/week increment in physical activity related energy expenditure, reduces the lifetime risk of type 2 diabetes by 9%.[58] A different study found that vigorous exercise at least once a week reduced the risk of type 2 diabetes in women by 33%.[59]
Protease inhibitors[edit]
Protease inhibitors found in HIV drugs are linked to insulin resistance.[60]
Cellular level[edit]
At the cellular level, much of the variance in insulin sensitivity between untrained, non-diabetic humans may be explained by two mechanisms: differences in phospholipid profiles of skeletal muscle cell membranes, and in intramyocellular lipid (ICML) stores within these cells.[61] High levels of lipids in the bloodstream have the potential to result in accumulation of triglycerides and their derivatives within muscle cells, which activate proteins Kinase C-ε and C-θ, ultimately reducing the glucose uptake at any given level of insulin.[28][62] This mechanism is quite fast-acting and may induce insulin resistance within days or even hours in response to a large lipid influx.[63] Draining the intracellular reserves, on the other hand, is more challenging: moderate caloric restriction alone, even over a period of several months, appears to be ineffective,[64][65] and it must be combined with physical exercise to have any effect.
In the long term, diet has the potential to change the ratio of polyunsaturated to saturated phospholipids in cell membranes, correspondingly changing cell membrane fluidity; full impact of such changes is not fully understood, but it is known that the percentage of polyunsaturated phospholipids is strongly inversely correlated with insulin resistance.[66] It is hypothesized that increasing cell membrane fluidity by increasing PUFA concentration might result in an enhanced number of insulin receptors, an increased affinity of insulin to its receptors, and a reduced insulin resistance, and vice versa.[67]
Many stressing factors may lead to increased cortisol in the bloodstream. Cortisol counteracts insulin, contributes to hyperglycemia-causing hepatic gluconeogenesis,[68] and inhibits the peripheral utilization of glucose, which eventually leads to insulin resistance.[68] It does this by decreasing the translocation of glucose transporters (especially GLUT4) to the cell membrane.[69][70]
Although inflammation often is caused by cortisol, inflammation by itself also seems to be implicated in causing insulin resistance. Mice without JNK1-signaling do not develop insulin resistance under dietary conditions that normally produce it.[71][72] Recent study have found out the specific role of the MLK family of protein in the activation of JNK during obesity and insulin resistance.[73]
Rare type 2 diabetes cases sometimes use high levels of exogenous insulin. As short-term overdosing of insulin causes short-term insulin resistance, it has been hypothesized that chronic high dosing contributes to more permanent insulin resistance.[citation needed]
Molecular[edit]
At a molecular level, insulin resistance has been proposed to be a reaction to excess nutrition by superoxide dismutase in cell mitochondria that acts as an antioxidant defense mechanism. This link seems to exist under diverse causes of insulin resistance. It also is based on the finding that insulin resistance may be reversed rapidly by exposing cells to mitochondrial uncouplers, electron transport chain inhibitors, or mitochondrial superoxide dismutase mimetics.[74]
Disease[edit]
Recent research and experimentation has uncovered a non-obesity related connection to insulin resistance and type 2 diabetes. It has long been observed that patients who have had some kinds of bariatric surgery have increased insulin sensitivity and even remission of type 2 diabetes. It was discovered that diabetic/insulin resistant non-obese rats whose duodenum has been removed surgically, also experienced increased insulin sensitivity[75] and remission of type 2 diabetes. This suggested similar surgery in humans, and early reports in prominent medical journals[76] are that the same effect is seen in humans, at least the small number who have participated in the experimental surgical program. The speculation is, that some substance is produced in the mucosa of that initial portion of the small intestine that signals body cells to become insulin resistant. If the producing tissue is removed, the signal ceases and body cells revert to normal insulin sensitivity. No such substance has been found as yet, and the existence of such a substance remains speculative.[citation needed]
Insulin resistance is associated with PCOS.[77]
HCV and insulin resistance[edit]
Hepatitis C also makes people three to four times more likely to develop type 2 diabetes and insulin resistance.[10] In addition, "people with Hepatitis C who develop diabetes probably have susceptible insulin-producing cells, and probably would get it anyway, but much later in life.[10] The extra insulin resistance caused by Hepatitis C apparently brings on diabetes at age 35 or 40, instead of 65 or 70."[10]
Pathophysiology[edit]
One of insulin's functions is to regulate delivery of glucose into cells to provide them with energy.[78] Insulin resistant cells cannot take in glucose, amino acids and fatty acids. Thus, glucose, fatty acids and amino acids 'leak' out of the cells. A decrease in insulin/glucagon ratio inhibits glycolysis which in turn decreases energy production. The resulting increase in blood glucose may raise levels outside the normal range and cause adverse health effects, depending on dietary conditions.[79] Certain cell types such as fat and muscle cells require insulin to absorb glucose. When these cells fail to respond adequately to circulating insulin, blood glucose levels rise. The liver helps regulate glucose levels by reducing its secretion of glucose in the presence of insulin. This normal reduction in the liver's glucose production may not occur in people with insulin resistance.[80]
Insulin resistance in muscle and fat cells reduces glucose uptake (and also local storage of glucose as glycogen and triglycerides, respectively), whereas insulin resistance in liver cells results in reduced glycogen synthesis and storage and also a failure to suppress glucose production and release into the blood. Insulin resistance normally refers to reduced glucose-lowering effects of insulin. However, other functions of insulin can also be affected. For example, insulin resistance in fat cells reduces the normal effects of insulin on lipids and results in reduced uptake of circulating lipids and increased hydrolysis of stored triglycerides. Increased mobilization of stored lipids in these cells elevates free fatty acids in the blood plasma. Elevated blood fatty-acid concentrations (associated with insulin resistance and diabetes mellitus Type 2), reduced muscle glucose uptake, and increased liver glucose production all contribute to elevated blood glucose levels. High plasma levels of insulin and glucose due to insulin resistance are a major component of the metabolic syndrome. If insulin resistance exists, more insulin needs to be secreted by the pancreas. If this compensatory increase does not occur, blood glucose concentrations increase and type 2 diabetes or latent autoimmune diabetes of adults occurs.[79][81]
Any food or drink containing glucose (or the digestible carbohydrates that contain it, such as sucrose, starch, etc.) causes blood glucose levels to increase. In normal metabolism, the elevated blood glucose level instructs beta (β) cells in the Islets of Langerhans, located in the pancreas, to release insulin into the blood. The insulin, in turn, makes insulin-sensitive tissues in the body (primarily skeletal muscle cells, adipose tissue, and liver) absorb glucose, and thereby lower the blood glucose level. The beta cells reduce insulin output as the blood glucose level falls, allowing blood glucose to settle at a constant of approximately 5 mmol/L (mM) (90 mg/dL). In an insulin-resistant person, normal levels of insulin do not have the same effect in controlling blood glucose levels. During the compensated phase on insulin resistance, insulin levels are higher, and blood glucose levels are still maintained. If compensatory insulin secretion fails, then either fasting (impaired fasting glucose) or postprandial (impaired glucose tolerance) glucose concentrations increase. Eventually, type 2 diabetes or latent autoimmune diabetes occurs when glucose levels become higher throughout the day as the resistance increases and compensatory insulin secretion fails. The elevated insulin levels also have additional effects (see insulin) that cause further abnormal biological effects throughout the body.[citation needed]
The most common type of insulin resistance is associated with overweight and obesity in a condition known as the metabolic syndrome. Insulin resistance often progresses to full Type 2 diabetes mellitus (T2DM) or latent autoimmune diabetes of adults.[82][83] This often is seen when hyperglycemia develops after a meal, when pancreatic β-cells are unable to produce sufficient insulin to maintain normal blood sugar levels (euglycemia) in the face of insulin resistance. The inability of the β-cells to produce sufficient insulin in a condition of hyperglycemia is what characterizes the transition from insulin resistance to T2DM.[84]
Various disease states make body tissues more resistant to the actions of insulin. Examples include infection (mediated by the cytokine TNFα) and acidosis. Recent research is investigating the roles of adipokines (the cytokines produced by adipose tissue) in insulin resistance. Certain drugs also may be associated with insulin resistance (e.g., glucocorticoids).[citation needed]
The presence of insulin leads to a kind of insulin resistance; every time a cell is exposed to insulin, the production of GLUT4 (Glucose transporter type 4) on the membrane of the cell decreases somewhat.[85] In the presence of a higher than usual level of insulin (generally caused by insulin resistance), this down-regulation acts as a kind of positive feedback, increasing the need for insulin. Exercise reverses this process in muscle tissue,[86] but if it is left unchecked, it may contribute to insulin resistance.
Elevated blood levels of glucose—regardless of cause—lead to increased glycation of proteins with changes, only a few of which are understood in any detail, in protein function throughout the body.[87][88]
Insulin resistance often is found in people with visceral adiposity (i.e., a high degree of fatty tissue within the abdomen—as distinct from subcutaneous adiposity or fat between the skin and the muscle wall, especially elsewhere on the body, such as hips or thighs), hypertension, hyperglycemia, and dyslipidemia involving elevated triglycerides, small dense low-density lipoprotein (sdLDL) particles, and decreased HDL cholesterol levels. With respect to visceral adiposity, a great deal of evidence suggests two strong links with insulin resistance. First, unlike subcutaneous adipose tissue, visceral adipose cells produce significant amounts of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-a), and Interleukins-1 and −6, etc. In numerous experimental models, these proinflammatory cytokines disrupt normal insulin action in fat and muscle cells, and may be a major factor in causing the whole-body insulin resistance observed in patients with visceral adiposity. Much of the attention on production of proinflammatory cytokines has focused on the IKK-beta/NF-kappa-B pathway, a protein network that enhances transcription of inflammatory markers and mediators that may cause insulin resistance. Second, visceral adiposity is related to an accumulation of fat in the liver, a condition known as non-alcoholic fatty liver disease (NAFLD). The result of NAFLD is an excessive release of free fatty acids into the bloodstream (due to increased lipolysis), and an increase in hepatic glycogenolysis and hepatic glucose production, both of which have the effect of exacerbating peripheral insulin resistance and increasing the likelihood of Type 2 diabetes mellitus.[citation needed]
Also, insulin resistance often is associated with a hypercoagulable state (impaired fibrinolysis) and increased inflammatory cytokine levels.[89]
Diagnosis[edit]
Fasting insulin levels[edit]
A fasting serum insulin level greater than 25 mIU/L or 174 pmol/L is considered insulin resistance. The same levels apply three hours after the last meal.[90]
Glucose tolerance testing (GTT)[edit]
During a glucose tolerance test, which may be used to diagnose diabetes mellitus, a fasting patient takes a 75 gram oral dose of glucose. Then blood glucose levels are measured over the following two hours.
Interpretation is based on WHO guidelines. After two hours a glycemia less than 7.8 mmol/L (140 mg/dL) is considered normal, a glycemia of between 7.8 and 11.0 mmol/L (140 to 197 mg/dL) is considered as impaired glucose tolerance (IGT), and a glycemia of greater than or equal to 11.1 mmol/L (200 mg/dL) is considered diabetes mellitus.
An oral glucose tolerance test (OGTT) may be normal or mildly abnormal in simple insulin resistance. Often, there are raised glucose levels in the early measurements, reflecting the loss of a postprandial peak (after the meal) in insulin production. Extension of the testing (for several more hours) may reveal a hypoglycemic "dip," that is a result of an overshoot in insulin production after the failure of the physiologic postprandial insulin response.[citation needed]
Measuring insulin resistance[edit]
Hyperinsulinemic euglycemic clamp[edit]
The gold standard for investigating and quantifying insulin resistance is the "hyperinsulinemic euglycemic clamp," so-called because it measures the amount of glucose necessary to compensate for an increased insulin level without causing hypoglycemia.[91] It is a type of glucose clamp technique. The test rarely is performed in clinical care, but is used in medical research, for example, to assess the effects of different medications. The rate of glucose infusion commonly is referred to in diabetes literature as the GINF value.[92]
The procedure takes about two hours. Through a peripheral vein, insulin is infused at 10–120 mU per m2 per minute. In order to compensate for the insulin infusion, glucose 20% is infused to maintain blood sugar levels between 5 and 5.5 mmol/L. The rate of glucose infusion is determined by checking the blood sugar levels every five to ten minutes.[92]
The rate of glucose infusion during the last thirty minutes of the test determines insulin sensitivity. If high levels (7.5 mg/min or higher) are required, the patient is insulin-sensitive. Very low levels (4.0 mg/min or lower) indicate that the body is resistant to insulin action. Levels between 4.0 and 7.5 mg/min are not definitive, and suggest "impaired glucose tolerance," an early sign of insulin resistance.[92]
This basic technique may be enhanced significantly by the use of glucose tracers. Glucose may be labeled with either stable or radioactive atoms. Commonly used tracers are 3-3H glucose (radioactive), 6,6 2H-glucose (stable) and 1-13C Glucose (stable). Prior to beginning the hyperinsulinemic period, a 3h tracer infusion enables one to determine the basal rate of glucose production. During the clamp, the plasma tracer concentrations enable the calculation of whole-body insulin-stimulated glucose metabolism, as well as the production of glucose by the body (i.e., endogenous glucose production).[92]
Modified insulin suppression test[edit]
Another measure of insulin resistance is the modified insulin suppression test developed by Gerald Reaven at Stanford University. The test correlates well with the euglycemic clamp, with less operator-dependent error. This test has been used to advance the large body of research relating to the metabolic syndrome.[92]
Patients initially receive 25 μg of octreotide (Sandostatin) in 5 mL of normal saline over 3 to 5 minutes via intravenous infusion (IV) as an initial bolus, and then, are infused continuously with an intravenous infusion of somatostatin (0.27 μg/m2/min) to suppress endogenous insulin and glucose secretion. Next, insulin and 20% glucose are infused at rates of 32 and 267 mg/m2/min, respectively. Blood glucose is checked at zero, 30, 60, 90, and 120 minutes, and thereafter, every 10 minutes for the last half-hour of the test. These last four values are averaged to determine the steady-state plasma glucose level (SSPG). Subjects with an SSPG greater than 150 mg/dL are considered to be insulin-resistant.[92]
Alternatives[edit]
Given the complicated nature of the "clamp" technique (and the potential dangers of hypoglycemia in some patients), alternatives have been sought to simplify the measurement of insulin resistance. The first was the Homeostatic Model Assessment (HOMA), and a more recent method is the Quantitative insulin sensitivity check index (QUICKI). Both employ fasting insulin and glucose levels to calculate insulin resistance, and both correlate reasonably with the results of clamping studies. Wallace et al. point out that QUICKI is the logarithm of the value from one of the HOMA equations.[93]
Management[edit]
The primary treatment for insulin resistance is exercise and weight loss. Research shows that a low-carbohydrate diet may help.[94] Both metformin and thiazolidinediones improve insulin resistance, but only are approved therapies for type 2 diabetes, not for insulin resistance. By contrast, growth hormone replacement therapy may be associated with increased insulin resistance.[95]
Metformin has become one of the more commonly prescribed medications for insulin resistance.[96] Unfortunately, Metformin also masks Vitamin B12 deficiency, so accompanying sub-lingual Vitamin B12 tablets are recommended.
Insulin resistance is often associated with abnormalities in lipids particularly high blood triglycerides and low high density lipoprotein.[18][28]
The Diabetes Prevention Program (DPP) showed that exercise and diet were nearly twice as effective as metformin at reducing the risk of progressing to type 2 diabetes.[97] However, the participants in the DPP trial regained about 40% of the weight that they had lost at the end of 2.8 years, resulting in a similar incidence of diabetes development in both the lifestyle intervention and the control arms of the trial.[98] One 2009 study found that carbohydrate deficit after exercise, but not energy deficit, contributed to insulin sensitivity increase.[99]
Resistant starch from high-amylose corn, amylomaize, has been shown to reduce insulin resistance in healthy individuals, in individuals with insulin resistance, and in individuals with type 2 diabetes.[100] Animal studies demonstrate that it cannot reverse damage already done by high glucose levels, but that it reduces insulin resistance and reduces the development of further damage.[101][102][103]
Some types of polyunsaturated fatty acids (omega-3) may moderate the progression of insulin resistance into type 2 diabetes,[104][105][106] however, omega-3 fatty acids appear to have limited ability to reverse insulin resistance, and they cease to be efficacious once type 2 diabetes is established.[107]
Caffeine intake limits insulin action, but not enough to increase blood-sugar levels in healthy persons. People who already have type 2 diabetes may see a small increase in levels if they take 2 or 2-1/2 cups of coffee per day.[108]
History[edit]
The concept that insulin resistance may be the underlying cause of diabetes mellitus type 2 was first advanced by Professor Wilhelm Falta and published in Vienna in 1931,[109] and confirmed as contributory by Sir Harold Percival Himsworth of the University College Hospital Medical Centre in London in 1936,[110] however, type 2 diabetes does not occur unless there is concurrent failure of compensatory insulin secretion.[111]
See also[edit]
Chronic Somogyi rebound
Hyperinsulinemia
Resistin
Chronic stress
Systemic inflammation
Circadian rhythm disruption
Advanced glycation end-products
PCOS
References[edit]
Jump up ^ Chiu HK, Tsai EC, Juneja R, et al. (August 2007). "Equivalent insulin resistance". Diabetes Research and Clinical Practice. 77: 237–44. PMID 17234296. doi:10.1016/j.diabres.2006.12.013.
^ Jump up to: a b c Wang, Guanyu (2014-12-06). "Raison d’être of insulin resistance: the adjustable threshold hypothesis". Journal of The Royal Society Interface. 11 (101): 20140892. ISSN 1742-5689. PMC 4223910  . PMID 25320065. doi:10.1098/rsif.2014.0892.
Jump up ^ "Insulin resistance: a marker of surgical stress : Current Opinion in Clinical Nutrition & Metabolic Care". LWW.
Jump up ^ Thorell, A.; Efendic, S.; Gutniak, M.; Häggmark, T.; Ljungqvist, O. (1994-01-01). "Insulin resistance after abdominal surgery". British Journal of Surgery. 81 (1): 59–63. ISSN 1365-2168. doi:10.1002/bjs.1800810120.
Jump up ^ Insulin resistance
Jump up ^ Cao, H. (2000-01-01). "Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy". Human Molecular Genetics. 9 (1): 109–112. ISSN 0964-6906. doi:10.1093/hmg/9.1.109.
Jump up ^ Musso, Carla; Cochran, Elaine; Moran, Stephanie Ann; Skarulis, Monica C.; Oral, Elif Arioglu; Taylor, Simeon; Gorden, Phillip (July 2004). "Clinical Course of Genetic Diseases of the Insulin Receptor (Type A and Rabson-Mendenhall Syndromes): A 30-Year Prospective". Medicine. 83 (4): 209–222. ISSN 0025-7974.
^ Jump up to: a b c d e f g h i j Mayfield, Jennifer (October 15, 1998). "Diagnosis and Classification of Diabetes Mellitus: New Criteria". American Academy of Family Physicians. Retrieved September 26, 2009.
^ Jump up to: a b c d e f g h "Type 2 diabetes: Risk factors". Mayo Clinic. Retrieved 21 December 2011.
^ Jump up to: a b c d Milner, KL; Van Der Poorten, D; Trenell, M; Jenkins, AB; Xu, A; Smythe, G; Dore, GJ; Zekry, A; et al. (2010). "Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance". Gastroenterology. 138 (3): 932–41.e3. PMID 19962985. doi:10.1053/j.gastro.2009.11.050. Lay summary – Science Daily (March 10, 2010).
Jump up ^ Yasuda, Keigo; Hines, III, Elbert; Kitabchi, Abbas E. (November 1982). "Hypercortisolism and insulin resistance: comparative effects of prednisone, hydrocortisone, and dexamethasone on insulin binding of human erythrocytes". Journal of Clinical Endocrinology & Metabolism. 55 (5): 910–15. PMID 6749880. doi:10.1210/jcem-55-5-910.
^ Jump up to: a b Wang, Guanyu (2010-01-01). "Singularity analysis of the AKT signaling pathway reveals connections between cancer and metabolic diseases". Physical Biology. 7 (4): 046015. ISSN 1478-3975. doi:10.1088/1478-3975/7/4/046015.
Jump up ^ Wang, Guanyu (2012-10-07). "Optimal homeostasis necessitates bistable control". Journal of The Royal Society Interface. 9 (75): 2723–2734. ISSN 1742-5689. PMC 3427521  . PMID 22535698. doi:10.1098/rsif.2012.0244.
Jump up ^ Lucidi, Paola; Rossetti, Paolo; Porcellati, Francesca; Pampanelli, Simone; Candeloro, Paola; Andreoli, Anna Marinelli; Perriello, Gabriele; Bolli, Geremia B.; Fanelli, Carmine G. (2010-06-01). "Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis". Diabetes. 59 (6): 1349–1357. ISSN 1939-327X. PMC 2874695  . PMID 20299466. doi:10.2337/db09-0745.
Jump up ^ "Tunable ultrasensitivity: functional decoupling and biological insights". Sci Rep. 6: 20345. Feb 5, 2016. doi:10.1038/srep20345.
Jump up ^ http://www.nature.com/nature/journal/v444/n7121/full/nature05482.html
Jump up ^ Kraegen, EW; Clark, PW; Jenkins, AB; Daley, EA; Chisholm, DJ; Storlien, LH (1991). "Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats". Diabetes. 40 (11): 1397–1403. PMID 1936601. doi:10.2337/diabetes.40.11.1397.
^ Jump up to: a b c d Storlien, LH; Jenkins, AB; Chisholm, DJ; Pascoe, WS; Khouri, S; Kraegen, EW (1991). "Influence of dietary fat composition on development of insulin resistance in rats". Diabetes. 40 (2): 280–9. PMID 1991575. doi:10.2337/diabetes.40.2.280.
Jump up ^ Lovejoy, J; Di Girolamo, M (1992). "Habitual dietary intake and insulin sensitivity in lean and obese adults". American Journal of Clinical Nutrition. 55 (6): 1174–9. PMID 1317665.
Jump up ^ Storlien, LH; Kraegen, E; Chisholm, D; Ford, G; Bruce, D; Pascoe, W (1987). "Fish oil prevents insulin resistance induced by high-fat feeding in rats". Science. 237 (4817): 885–88. Bibcode:1987Sci...237..885S. PMID 3303333. doi:10.1126/science.3303333.
Jump up ^ Lovejoy, Jennifer C. (1 October 1999). "Dietary fatty acids and insulin resistance". Current Atherosclerosis Reports. 1 (3): 215–20. PMID 11122713. doi:10.1007/s11883-999-0035-5.
Jump up ^ Kelley, Darshan S; Vemuri, Madhuri; Adkins, Yuriko; Gill, Sher Himmat S.; Fedor, Dawn; MacKey, Bruce E. (2008). "Flaxseed oil prevents trans-10, cis-12-conjugated linoleic acid-induced insulin resistance in mice" (PDF). British Journal of Nutrition. 101 (5): 701–8. PMID 18710604. doi:10.1017/s0007114508027451.
Jump up ^ Mozaffarian, Dariush; Ascherio, A; Hu, FB; Stampfer, MJ; Willett, WC; Siscovick, DS; Rimm, EB (2004). "Interplay between different polyunsaturated fatty acids and risk of coronary heart disease in men". Circulation. 111 (2): 157–64. PMC 1201401  . PMID 15630029. doi:10.1161/01.CIR.0000152099.87287.83.
Jump up ^ Wilkinson, Paul; Leach, C; Ah-Sing, EE; Hussain, N; Miller, GJ; Millward, DJ; Griffin, BA (2004). "Influence of α-linolenic acid and fish-oil on markers of cardiovascular risk in subjects with an atherogenic lipoprotein phenotype". Atherosclerosis. 181 (1): 115–24. PMID 15939062. doi:10.1016/j.atherosclerosis.2004.12.029.
Jump up ^ Ebbesson, SO; Kennish, J; Ebbesson, L; Go, O; Yeh, J (1999). "Diabetes is related to fatty acid imbalance in Eskimos". Int J Circumpolar Health. 58 (2): 108–19. PMID 10429340.
Jump up ^ Ebbesson, SO; Ebbesson, Lars OE; Swenson, Michael; Kennish, John M; Robbins, David C (2005). "A successful diabetes prevention study in Eskimos: the Alaska Siberia project" (PDF). Int J Circumpolar Health. 64 (4). doi:10.3402/ijch.v64i4.18017.
Jump up ^ "Dietary fats: total fat and fatty acids" (PDF). USDA.
^ Jump up to: a b c Schinner, S; Scherbaum, WA; Bornstein, SR; Barthel, A (2005). "Molecular mechanisms of insulin resistance". Diabetic Medicine. 22 (6): 674–82. PMID 15910615. doi:10.1111/j.1464-5491.2005.01566.x.
Jump up ^ Koyama, Kazunori; Chen, G; Lee, Y; Unger, RH (1997). "Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity". American Journal of Physiology. 273 (4 Pt 1): E708–13. PMID 9357799.
Jump up ^ Roden, Michael; Price, TB; Perseghin, G; Petersen, KF; Rothman, DL; Cline, GW; Shulman, GI (1996). "Mechanism of free fatty acid-induced insulin resistance in humans". Journal of Clinical Investigation. 97 (12): 2859–65. PMC 507380  . PMID 8675698. doi:10.1172/JCI118742.
Jump up ^ "Obesity and elevated triglycerides". Med scape.
Jump up ^ Olefsky, J; Crapo, PA; Ginsberg, H; Reaven, GM (1975). "Metabolic effects of increased caloric intake in man". Metabolism. 24 (4): 495–503. PMID 1117841. doi:10.1016/0026-0495(75)90074-8.
Jump up ^ Parks, EJ; Krauss, RM; Christiansen, MP; Neese, RA; Hellerstein, MK (October 1999). "Effects of a low-fat, high-carbohydrate diet on VLDL-triglyceride assembly, production, and clearance". Journal of Clinical Investigation. 104 (8): 1087–96. PMC 408572  . PMID 10525047. doi:10.1172/JCI6572.
Jump up ^ Taubes, Gary (April 13, 2011). "Is sugar toxic?". The New York Times.
Jump up ^ Basciano, Heather; Federico, Lisa; Adeli, Khosrow (2005). "Fructose, insulin resistance, and metabolic dyslipidemia". Nutrition & Metabolism. 2 (1): 5. PMC 552336  . PMID 15723702. doi:10.1186/1743-7075-2-5.
Jump up ^ Thorburn, Anne W (1989). "Fructose-induced in vivo insulin resistance and elevated plasma triglyceride levels in rats" (PDF). American Journal of Clinical Nutrition.
Jump up ^ Hwang, IS (1987). "Fructose-induced insulin resistance and hypertension in rats" (PDF). Hypertension. 10: 512–516. doi:10.1161/01.HYP.10.5.512.
Jump up ^ Huang, YJ; Fang, VS; Juan, CC; Chou, YC; Kwok, CF; Ho, LT (November 1997). "Amelioration of insulin resistance and hypertension in a fructose-fed rat model with fish oil supplementation". Metab. Clin. Exp. 46 (11): 1252–58. PMID 9361681. doi:10.1016/S0026-0495(97)90226-2.
Jump up ^ Hudgins, Lisa C (2000-12-01). "Effect of high-carbohydrate feeding on triglyceride and saturated fatty acid synthesis". Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine. 225 (3): 178–83. PMID 11082210. doi:10.1111/j.1525-1373.2000.22521.x.
Jump up ^ Esmaillzadeh, Ahmad; Kimiagar, M; Mehrabi, Y; Azadbakht, L; Hu, FB; Willett, WC (2006). "Fruit and vegetable intakes, C-reactive protein, and the metabolic syndrome". American Journal of Clinical Nutrition. 84 (6): 1489–97. PMID 17158434.
Jump up ^ McKeown, Nicola M; Meigs, JB; Liu, S; Saltzman, E; Wilson, PWF; Jacques, PF (2004). "Carbohydrate Nutrition, Insulin Resistance, and the Prevalence of the Metabolic Syndrome in the Framingham Offspring Cohort". Diabetes Care. 27 (2): 538–46. PMID 14747241. doi:10.2337/diacare.27.2.538.
Jump up ^ "Leptin Resistance and Obesity" (PDF). Leptin research.
Jump up ^ Wang, J; Obici, S; Morgan, K; Barzilai, N; Feng, Z; Rossetti, L (2001). "Overfeeding rapidly induces leptin and insulin resistance". Diabetes. 50 (12): 2786–91. PMID 11723062. doi:10.2337/diabetes.50.12.2786.
Jump up ^ Shapiro, Alexandra; Mu, W; Roncal, C; Cheng, K-Y; Johnson, RJ; Scarpace, PJ (2008). "Fructose-induced leptin resistance exacerbates weight gain in response to subsequent high-fat feeding". American Journal of Physiology. 295 (5): R1370–375. PMC 2584858  . PMID 18703413. doi:10.1152/ajpregu.00195.2008.
Jump up ^ Janket, SJ; Manson, JE; Sesso, H; Buring, JE; Liu, S (2003). "A prospective study of sugar intake and risk of type 2 diabetes in women". Diabetes Care. 26 (4): 1008–15. PMID 12663565. doi:10.2337/diacare.26.4.1008.
^ Jump up to: a b Isganaitis, Elvira; Lustig, Robert H (2005). "Fast Food, Central Nervous System Insulin Resistance, and Obesity". Arteriosclerosis, Thrombosis, and Vascular Biology. 25 (12): 2451–62. PMID 16166564. doi:10.1161/01.ATV.0000186208.06964.91.
Jump up ^ Unger, Roger H; Scherer, Philipp E (2010). "Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity" (PDF). Trends in Endocrinology & Metabolism.
Jump up ^ Pham, T; Cornea, A; Blick, KE; Jenkins, A; Scofield, RH (2007). "Oral glucosamine in doses used to treat osteoarthritis worsens insulin resistance". The American journal of the medical sciences. 333 (6): 333–39. PMID 17570985. doi:10.1097/MAJ.0b013e318065bdbe.
Jump up ^ Muniyappa R, Karne RJ, Hall G, et al. (November 2006). "Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects". Diabetes. 55 (11): 3142–50. PMID 17065354. doi:10.2337/db06-0714.
Jump up ^ Pouwels MJ, Jacobs JR, Span PN, Lutterman JA, Smits P, Tack CJ; Jacobs; Span; Lutterman; Smits; Tack (May 2001). "Short-term glucosamine infusion does not affect insulin sensitivity in humans". The Journal of Clinical Endocrinology and Metabolism. 86 (5): 2099–103. PMID 11344213. doi:10.1210/jc.86.5.2099. CS1 maint: Multiple names: authors list (link)
Jump up ^ Biggee BA, Blinn CM, Nuite M, Silbert JE, McAlindon TE; Blinn; Nuite; Silbert; McAlindon (February 2007). "Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis". Annals of the Rheumatic Diseases. 66 (2): 260–2. PMC 1798503  . PMID 16818461. doi:10.1136/ard.2006.058222. CS1 maint: Multiple names: authors list (link)
Jump up ^ Giovannini, C; Sellini, M; Manzo, G; Barletta, C; Scavo, D (February 1982). "Influenza, nel soggetto normale, della dieta normocalorica i- perproteica su la risposta del cortisolo, dello ACTH, del GH e della PRL alla ipoglicemia insulinica" [The influence, in normal subjects, of a high-protein normocaloric diet on the response of cortisol, ACTH, GH, and PRL to insulin hypoglycemia]. Boll. Soc. Ital. Biol. Sper. (in Italian). 58 (3–4): 121–7. PMID 6279131.
Jump up ^ Sluijs, I; Beulens, JW; van der A, DL; Spijkerman, AM; Grobbee, DE; van der Schouw, YT (January 2010). "Dietary intake of total, animal, and vegetable protein and risk of type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC)-NL study". Diabetes Care. 33 (1): 43–48. PMC 2797984  . PMID 19825820. doi:10.2337/dc09-1321.
Jump up ^ Vuorinen-Markkola, H; Yki-Järvinen, H (January 1994). "Hyperuricemia and insulin resistance". J. Clin. Endocrinol. Metab. 78 (1): 25–9. PMID 8288709. doi:10.1210/jc.78.1.25.
Jump up ^ Chiu, KC; Chu, A; Go, VL; Saad, MF (2004). "Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction". The American Journal of Clinical Nutrition. 79 (5): 820–5. PMID 15113720.
Jump up ^ Ivy, JL (November 1997). "Role of exercise training in the prevention and treatment of insulin resistance and non-insulin-dependent diabetes mellitus". Sports Medicine. Auckland, NZ. 24 (5): 321–36. PMID 9368278. doi:10.2165/00007256-199724050-00004.
Jump up ^ Mayer-Davis, EJ; d'Agostino jr, R; Karter, AJ; Haffner, SM; Rewers, MJ; Saad, M; Bergman, RN (1998). "Intensity and amount of physical activity in relation to insulin sensitivity". JAMA: The Journal of the American Medical Association. 279 (9): 669–74. PMID 9496984. doi:10.1001/jama.279.9.669.
Jump up ^ Helmrich, Susan P; Ragland, David R; Leung, Rita W; Paffenbarger, Ralph S (1991). "Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus". New England Journal of Medicine. 325 (3): 147–52. PMID 2052059. doi:10.1056/NEJM199107183250302.
Jump up ^ Manson, JE; Rimm, EB; Stampfer, MJ; Willett, WC; Rosner, B; Hennekens, CH; Speizer, FE; Rimm, EB; Krolewski, AS (September 1991). "Physical activity and incidence of non-insulin-dependent diabetes mellitus in women". Lancet. 338 (8770): 774–778. PMID 1681160. doi:10.1016/0140-6736(91)90664-B.
Jump up ^ Fantry, Lori E (2003-03-24). "Protease Inhibitor-Associated Diabetes Mellitus: A Potential Cause of Morbidity and Mortality". JAIDS: Journal of Acquired Immune Deficiency Syndromes. Lippincott Williams & Wilkins. 32 (3){{inconsistent citations}} .
Jump up ^ Haag, Marianne; Dippenaar, Nola G. (December 2005). "Dietary fats, fatty acids and insulin resistance: short review of a multifaceted connection" (PDF). Medical Science Monitor. 11 (12): RA359–67. PMID 16319806. Archived from the original (PDF) on 2011-10-08.
Jump up ^ Morino, K; Petersen, K; Shulman, G (2006). "Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction". Diabetes. 55 Suppl 2 (Suppl 2): S9–15. PMC 2995546  . PMID 17130651. doi:10.2337/db06-S002.
Jump up ^ Bachman, O; Dahl, DB; Brechtel, K; Machann, J; Haap, M; Maier, T; Loviscach, M; Stumvoll, M; et al. (2001). "Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans" (PDF). Diabetes. 50 (11): 2579–84. PMID 11679437. doi:10.2337/diabetes.50.11.2579.
Jump up ^ Sato, F; Tamura, Y; Watada, H; Kumashiro, N; Igarashi, Y; Uchino, H; Maehara, T; Kyogoku, S; et al. (2007). "Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects". The Journal of Clinical Endocrinology and Metabolism. 92 (8): 3326–29. PMID 17519317. doi:10.1210/jc.2006-2384.
Jump up ^ Tamura, Y; Tanaka, Y; Sato, F; Choi, JB; Watada, H; Niwa, M; Kinoshita, J; Ooka, A; et al. (2005). "Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients". The Journal of Clinical Endocrinology and Metabolism. 90 (6): 3191–96. PMID 15769987. doi:10.1210/jc.2004-1959.
Jump up ^ Haugaard, SB; Madsbad, Sten; Hoy, Carl-Erik; Vaag, Allan (2006). "Dietary intervention increases n-3 long-chain polyunsaturated fatty acids in skeletal muscle membrane phospholipids of obese subjects. Implications for insulin sensitivity". Clin Endocrinol. 64 (2): 169–78. PMID 16430716. doi:10.1111/j.1365-2265.2006.02444.x.
Jump up ^ Russo, Gian Luigi (2009). "Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention" (PDF). Biochemical Pharmacology. 77 (6): 937–46. PMID 19022225. doi:10.1016/j.bcp.2008.10.020.
^ Jump up to: a b Brown, Dave D (2003). USMLE Step 1 Secrets. p. 63.
Jump up ^ King, Michael W (2005). Lange Q&A USMLE Step 1 (6th ed.). New York: McGraw-Hill Medical. p. 82. ISBN 0-07-144578-1.
Jump up ^ Piroli, GG; Grillo, CA; Reznikov, LR; Adams, S; McEwen, BS; Charron, MJ; Reagan, LP (2007). "Corticosterone Impairs Insulin-Stimulated Translocation of GLUT4 in the Rat Hippocampus". Neuroendocrinology. 85 (2): 71–80. PMID 17426391. doi:10.1159/000101694.
Jump up ^ Solinas, G; Vilcu, C; Neels, JG; Bandyopadhyay, GK; Luo, JL; Naugler, W; Grivennikov, S; Wynshaw-Boris, A; et al. (2007). "JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity". Cell Metabolism. 6 (5): 386–97. PMID 17983584. doi:10.1016/j.cmet.2007.09.011.
Jump up ^ "UCSD researchers discover inflammation, not obesity, cause of insulin resistance". D life. Retrieved 2008-01-12.
Jump up ^ | Kant, S; Barrett, T; Vertii, A; Noh, YH; Jung, DY; Kim, JK; Davis, RJ (2013). "Role of the mixed-lineage protein kinase pathway in the metabolic stress response to obesity". Cell Rep. 4 (4): 681–8. PMC 3769115  . PMID 23954791. doi:10.1016/j.celrep.2013.07.019.
Jump up ^ Hoehn, KL; Salmon, AB; Hohnen-Behrens, C; Turner, N; Hoy, AJ; Maghzal, GJ; Stocker, R; Van Remmen, H; et al. (2009). "Insulin resistance is a cellular antioxidant defense mechanism". Proceedings of the National Academy of Sciences of the United States of America. 106 (42): 17787–92. PMC 2764908  . PMID 19805130. doi:10.1073/pnas.0902380106.
Jump up ^ Garrido-Sanchez, L. "Bypass of the duodenum improves insulin resistance much more rapidly than sleeve gastrectomy". Surgery or obesity and related diseases. 8 (2): 145–150. doi:10.1016/j.soard.2011.03.010. Retrieved 12 March 2017.
Jump up ^ Goodman, Alice (June 1, 2016). "Duodenal resurfacing achieves metabolic benefits in type 2 diabetes". Family Practice News. Retrieved 12 March 2017.
Jump up ^ Nafiye, Y; Sevtap, K; Muammer, D; Emre, O; Senol, K; Leyla, M (Apr 2010). "The effect of serum and intrafollicular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome.". Fertility and Sterility. 93 (6): 1864–9. PMID 19171332. doi:10.1016/j.fertnstert.2008.12.024.
Jump up ^ "A heavy burden". The Economist. December 15, 2012. Retrieved 10 January 2013.
^ Jump up to: a b "Insulin resistance". Medicine net.
Jump up ^ "Science daily". Jun 2009.
Jump up ^ Insulin Resistance Leads to LADA (Report). Diabetes Health. Retrieved Feb 21, 2015.
Jump up ^ Behme MT, Dupre J, Harris SB, Hramiak IM, Mahon JL. "Insulin Resistance/LADA". Ann N Y Acad Sci. 1005: 374–7. PMID 14679095. doi:10.1196/annals.1288.062.
Jump up ^ "Latent Autoimmune Diabetes: A Little Known Type of Diabetes". Pharmacy Times. Retrieved May 30, 2014.
Jump up ^ McGarry, JD (2002). "Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes". Diabetes. 51 (1): 7–18. PMID 11756317. doi:10.2337/diabetes.51.1.7.
Jump up ^ Flores-Riveros, JR; McLenithan, JC; Ezaki, O; Lane, MD (1993). "Insulin down-regulates expression of the insulin-responsive glucose transporter (GLUT4) gene: effects on transcription and mRNA turnover". Proceedings of the National Academy of Sciences of the United States of America. 90 (2): 512–516. PMC 45693  . PMID 8421683. doi:10.1073/pnas.90.2.512.
Jump up ^ MacLean, PS; Zheng, D; Jones, JP; Olson, AL; Dohm, GL (2002). "Exercise-induced transcription of the muscle glucose transporter (GLUT 4) gene". Biochemical and Biophysical Research Communications. 292 (2): 409–414. PMID 11906177. doi:10.1006/bbrc.2002.6654.
Jump up ^ Koga M, Kasayama S (2010). "Clinical impact of glycated albumin as another glycemic control marker". Endocrine Journal. 57 (9): 751–762. PMID 20724796. doi:10.1507/endocrj.K10E-138.
Jump up ^ Puddu A, Viviani GL (2011). "Advanced glycation endproducts and diabetes. Beyond vascular complications". Endocrine, Metabolic & Immune Disorders Drug Targets. 11 (2): 132–140. PMID 21476962. doi:10.2174/187153011795564115.
Jump up ^ Nagaev, I; Bokarewa, M; Tarkowski, A; Smith, U (2006). Valcarcel, Juan, ed. "Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes". PLoS ONE. 1 (1): e31. PMC 1762367  . PMID 17183659. doi:10.1371/journal.pone.0000031.
Jump up ^ Insulin at eMedicine
Jump up ^ Defronzo, RA; Tobin, JD; Andres, R (1979). "Glucose clamp technique: a method for quantifying insulin secretion and resistance". The American journal of physiology. 237 (3): E214–23. PMID 382871.
^ Jump up to: a b c d e f Muniyappa, R; Lee, S; Chen, H; Quon, MJ (2008). "Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage". Am J Physiol Endocrinol Metab. 294 (1): E15–E26. PMID 17957034. doi:10.1152/ajpendo.00645.2007.
Jump up ^ Wallace, TM; Levy, JC; Matthews, DR (2004). "Use and abuse of HOMA modeling". Diabetes Care. 27 (6): 1487–1495. PMID 15161807. doi:10.2337/diacare.27.6.1487.
Jump up ^ Boden, G; Sargrad, K; Homko, C; Mozzoli, M; Stein, TP (2005). "Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes". Annals of Internal Medicine. 142 (6): 403–11. PMID 15767618. doi:10.7326/0003-4819-142-6-200503150-00006.
Jump up ^ Bramnert, M; Segerlantz, M; Laurila, E; Daugaard, JR; Manhem, P; Groop, L (2003). "Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle". The Journal of Clinical Endocrinology and Metabolism. 88 (4): 1455–1463. PMID 12679422. doi:10.1210/jc.2002-020542.
Jump up ^ ncbi.nlm.nih.gov
Jump up ^ Knowler, WC; Barrett-Connor, E; Fowler, SE; Hamman, RF; Lachin, JM; Walker, EA; Nathan, DM (2002). "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin". New England Journal of Medicine. Diabetes Prevention Program Research Group. 346 (6): 393–403. PMC 1370926  . PMID 11832527. doi:10.1056/NEJMoa012512.
Jump up ^ Kahn, R. (January 2012). "Reducing the impact of diabetes: Is prevention feasible today, or should we aim for better treatment?". Health Affairs. 31 (1): 76–83. PMID 22232097. doi:10.1377/hlthaff.2011.1075.
Jump up ^ Newsom, S. A.; Schenk, S.; Thomas, K. M.; Harber, M. P.; Knuth, N. D.; Goldenberg, N.; Horowitz, J. F. (2009). "Energy deficit after exercise augments lipid mobilization but does not contribute to the exercise-induced increase in insulin sensitivity". Journal of Applied Physiology. 108 (3): 554–560. PMC 2838634  . PMID 20044472. doi:10.1152/japplphysiol.01106.2009.
Jump up ^ Keenan, M. J.; Zhou, J.; Hegsted, M.; Pelkman, C.; Durham, H. A.; Coulon, D. B.; Martin, R. J. (Mar 2015). "Role of resistant starch in improving gut health, adiposity, and insulin resistance". Advances in Nutrition. 6 (2): 198–205. PMC 4352178  . PMID 25770258. doi:10.3945/an.114.007419.
Jump up ^ Higgins, JA; Miller Brand, JC; Denyer, GS (1996). "Development of insulin resistant in the rat is dependent on the rate of glucose absorption from the diet". Journal of Nutrition. 126 (3): 596–602. PMID 8598543.
Jump up ^ Byrnes, SE; Brand Miller, JC; Denyer, GS (1995). "Amylopectin starch promotes the development of insulin resistance in rats". Journal of Nutrition. 125 (6): 1430–37. PMID 7782895.
Jump up ^ Wiseman, CE; Higgins, JA; Denyer, GS; Brand Miller, JC (1996). "Amylopectin starch induces nonreversible insulin resistance in rats". Journal of Nutrition. 126 (2): 410–415. PMID 8632213.
Jump up ^ Lovejoy, Jennifer C (2002). "The influence of dietary fat on insulin resistance". Current Diabetes Reports. 2 (5): 435–40. PMID 12643169. doi:10.1007/s11892-002-0098-y.
Jump up ^ Fukuchi, S; Hamaguchi, K; Seike, M; Himeno, K; Sakata, T; Yoshimatsu, H (2004). "Role of fatty acid composition in the development of metabolic disorders in sucrose-induced obese rats". Experimental biology and medicine. 229 (6): 486–93. PMID 15169967.
Jump up ^ Storlien, LH; Baur, LA; Kriketos, AD; Pan, DA; Cooney, GJ; Jenkins, AB; Calvert, GD; Campbell, LV (1996). "Dietary fats and insulin action". Diabetologia. 39 (6): 621–31. PMID 8781757. doi:10.1007/BF00418533.
Jump up ^ De la Rue, J; Lefoll, C; Corporeau, C; Lucas, D (2004). "N-3 long chain polyunsaturated fatty acids: a nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity?". Reproduction, nutrition, development. 44 (3): 289–99. PMID 15460168. doi:10.1051/rnd:2004033.
Jump up ^ "Does caffeine affect blood sugar?". Mayo Clinic{{inconsistent citations}}
Jump up ^ Falta, W.; Boller, R. (1931). "Insulärer und Insulinresistenter Diabetes". Klinische Wochenschrift. 10 (10): 438–443. doi:10.1007/BF01736348.
Jump up ^ Himsworth, H (1936). "Diabetes mellitus: its differentiation into insulin-sensitive and insulin insensitive types". The Lancet. 227 (5864): 127–130. doi:10.1016/S0140-6736(01)36134-2.
Jump up ^ Nolan, C (2010). "Failure of islet β-cell compensation for insulin resistance causes type 2 diabetes: What causes non-alcoholic fatty liver disease and non-alcoholic steatohepatitis?". Journal of Gastroenterology and Hepatology. 25 (10): 1594–1597. PMID 20880166. doi:10.1111/j.1440-1746.2010.06473.x.
Further reading[edit]
Reaven GM (2005). "The insulin resistance syndrome: definition and dietary approaches to treatment". Annual Review of Nutrition (review). 25: 391–406. PMID 16011472. doi:10.1146/annurev.nutr.24.012003.132155.
Rao, Goutham (2001). "Insulin resistance syndrome". American Family Physician (review). US. 63 (6): 1159–63, 1165–6. PMID 11277552.
External links[edit]
Insulin resistance at DMOZ
"The National Insulin Resistance Council". US.
"Insulin resistance". Diabetes. US: NIH.
[show]
v
t
e
Diabetes (E10–E14, 250)
Types
Type 1
Type 2
LADA
Gestational diabetes
Diabetes and pregnancy
Prediabetes
Impaired fasting glucose
Impaired glucose tolerance
Insulin resistance
KPD
MODY
Neonatal
Transient
Permanent
Type 3c (Pancreatogenic)
Blood tests
Blood sugar level
Glycosylated hemoglobin
Glucose tolerance test
Postprandial glucose test
Fructosamine
Glucose test
C-peptide
Noninvasive glucose monitor
Insulin tolerance test
Management
Diabetic diet
Anti-diabetic drugs
Insulin therapy
intensive
conventional
pulsatile
Cure
Embryonic stem cells
Artificial pancreas
Other
Gastric bypass surgery
Complications
Diabetic comas
Hypoglycemia
Ketoacidosis
Hyperosmolar hyperglycemic state
Diabetic foot
ulcer
Neuropathic arthropathy
Organs in diabetes
Blood vessels
Muscle
Kidney
Nerves
Retina
Heart
Diabetic skin disease
Diabetic dermopathy
Diabetic bulla
Diabetic cheiroarthropathy
Neuropathic ulcer
Hyperglycemia
Hypoglycemia
Other
Glossary of diabetes
Notable people with type 1 diabetes
[show]
v
t
e
Diseases of the endocrine system (E00–E35, 240–259)
Pancreas/
glucose
metabolism
Hypofunction
Diabetes mellitus
types:
type 1
type 2
gestational
MODY 1 2 3 4 5 6
complications
coma
angiopathy
ketoacidosis
nephropathy
neuropathy
retinopathy
cardiomyopathy
insulin receptor (Rabson–Mendenhall syndrome)
Insulin resistance
Hyperfunction
Hypoglycemia
beta cell (Hyperinsulinism)
G cell (Zollinger–Ellison syndrome)
Hypothalamic/
pituitary axes
Hypothalamus
gonadotropin
Kallmann syndrome
Adiposogenital dystrophy
CRH (Tertiary adrenal insufficiency)
vasopressin (Neurogenic diabetes insipidus)
general (Hypothalamic hamartoma)
Pituitary
Hyperpituitarism
anterior
Acromegaly
Hyperprolactinaemia
Pituitary ACTH hypersecretion
posterior (SIADH)
general (Nelson's syndrome)
Hypopituitarism
anterior
Kallmann syndrome
Growth hormone deficiency
Hypoprolactinemia
ACTH deficiency/Secondary adrenal insufficiency
GnRH insensitivity
FSH insensitivity
LH/hCG insensitivity
posterior (Neurogenic diabetes insipidus)
general
Empty sella syndrome
Pituitary apoplexy
Sheehan's syndrome
Lymphocytic hypophysitis
Thyroid
Hypothyroidism
Iodine deficiency
Cretinism
Congenital hypothyroidism
Myxedema
Euthyroid sick syndrome
Hyperthyroidism
Hyperthyroxinemia
Thyroid hormone resistance
Familial dysalbuminemic hyperthyroxinemia
Hashitoxicosis
Thyrotoxicosis factitia
Graves' disease
Thyroiditis
Acute infectious
Subacute
De Quervain's
Subacute lymphocytic
Autoimmune/chronic
Hashimoto's
Postpartum
Riedel's
Goitre
Endemic goitre
Toxic nodular goitre
Toxic multinodular goiter
Thyroid nodule
Parathyroid
Hypoparathyroidism
Hypoparathyroidism
Pseudohypoparathyroidism
Pseudopseudohypoparathyroidism
Hyperparathyroidism
Primary
Secondary
Tertiary
Osteitis fibrosa cystica
Adrenal
Hyperfunction
aldosterone: Hyperaldosteronism/Primary aldosteronism
Conn syndrome
Bartter syndrome
Glucocorticoid remediable aldosteronism
AME
Liddle's syndrome
17α CAH
cortisol: Cushing's syndrome (Pseudo-Cushing's syndrome)
sex hormones: 21α CAH
11β CAH
Hypofunction/
Adrenal insufficiency
(Addison's, WF)
aldosterone: Hypoaldosteronism
21α CAH
11β CAH
cortisol: CAH
Lipoid
3β
11β
17α
21α
sex hormones: 17α CAH
Gonads
ovarian: Polycystic ovary syndrome
Premature ovarian failure
testicular: enzymatic
5α-reductase deficiency
17β-hydroxysteroid dehydrogenase deficiency
aromatase excess syndrome
Androgen receptor (Androgen insensitivity syndrome)
general: Hypogonadism (Delayed puberty)
Hypergonadism
Precocious puberty
Hypoandrogenism
Hypoestrogenism
Hyperandrogenism
Hyperestrogenism
Postorgasmic illness syndrome
Height
Dwarfism/Short stature
Midget
Laron syndrome
Psychosocial
Ateliosis
Gigantism
Multiple
Autoimmune polyendocrine syndrome multiple
APS1
APS2
Carcinoid syndrome
Multiple endocrine neoplasia
1
2A
2B
Progeria
Werner syndrome
Acrogeria
Metageria
Woodhouse–Sakati syndrome
Retrieved from "https://en.wikipedia.org/w/index.php?title=Insulin_resistance&oldid=807750390"
Categories:
Diabetes
Hidden categories:
CS1 maint: Multiple names: authors list
CS1 Italian-language sources (it)
Articles needing additional medical references from October 2015
All articles needing additional references
All articles with unsourced statements
Articles with unsourced statements from October 2010
Articles with DMOZ links
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Article
Talk
Variants
Views
Read
Edit
View history
More
Search
Navigation
Main page
Contents
Featured content
Current events
Random article
Donate to Wikipedia
Wikipedia store
Interaction
Help
About Wikipedia
Community portal
Recent changes
Contact page
Tools
What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Wikidata item
Cite this page
Print/export
Create a book
Download as PDF
Printable version
In other projects
Wikimedia Commons
Languages
Afrikaans
العربية
Български
Bosanski
Català
Deutsch
Español
Esperanto
فارسی
Français
한국어
Bahasa Indonesia
Italiano
Bahasa Melayu
日本語
Polski
Português
Română
Русский
Simple English
Suomi
Svenska
Türkçe
中文
Edit links
This page was last edited on 29 October 2017, at 22:54.
Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.
Privacy policy
About Wikipedia
Disclaimers
Contact Wikipedia
Developers
Cookie statement
Mobile view
Enable previews

key: html

type: local

value: div

attrs: id class

values: mw-page-base noprint

values: mw-head-base noprint

value: a

attrs: id class lang

values: firstHeading firstHeading en

values: siteSub noprint

values: jump-to-nav mw-jump

value: img

attrs: alt src width height srcset data-file-width data-file-height

value: td

attrs: href title

values: Wikipedia:Identifying reliable sources (medicine)

attrs: class href

value: span

value: i

value: small

attrs: href class

values:
plainlinks metadata ambox ambox-content
presentation

values:
/wiki/Blood_sugar
mw-redirect
Blood sugar

values:
/wiki/Risk_factors
mw-redirect
Risk factors

values: This claim needs references to reliable sources. (October 2010)

values:
noprint Inline-Template Template-Fact
white-space:nowrap;

values:
/wiki/Free_fatty_acid
mw-redirect
Free fatty acid

values:
/wiki/Simple_sugar
mw-redirect
Simple sugar

values:
/wiki/Adipose_cells
mw-redirect
Adipose cells

values:
/wiki/Protease_inhibitors
mw-redirect
Protease inhibitors

values:
/wiki/Cell_membranes
mw-redirect
Cell membranes

values: Edit section: HCV and insulin resistance

values:
/wiki/Blood_glucose_level
mw-redirect
Blood glucose level

values:
/wiki/Islets_of_Langerhans
mw-redirect
Islets of Langerhans

values:
/wiki/Tumor_necrosis_factor-alpha
mw-redirect
Tumor necrosis factor-alpha

values:
/wiki/Hypercoagulable_state
mw-redirect
Hypercoagulable state

values: Edit section: Glucose tolerance testing (GTT)

values:
/wiki/Oral_glucose_tolerance_test
mw-redirect
Oral glucose tolerance test

values: Edit section: Measuring insulin resistance

values: Edit section: Hyperinsulinemic euglycemic clamp

values:
/wiki/Peripheral_vein
mw-redirect
Peripheral vein

values: Edit section: Modified insulin suppression test

values: Quantitative insulin sensitivity check index

values:
/wiki/Advanced_glycation_end-products
mw-redirect
Advanced glycation end-products

values:
/wiki/PubMed_Identifier
mw-redirect
PubMed Identifier

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17234296

values:
nofollow
external text
//www.worldcat.org/issn/1742-5689

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/25320065

values:
nofollow
external text
//doi.org/10.1098%2Frsif.2014.0892

values:
nofollow
external text
//www.worldcat.org/issn/1365-2168

values:
nofollow
external text
//doi.org/10.1002%2Fbjs.1800810120

values:
nofollow
external text
//www.worldcat.org/issn/0964-6906

values:
nofollow
external text
//doi.org/10.1093%2Fhmg%2F9.1.109

values:
nofollow
external text
//www.worldcat.org/issn/0025-7974

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19962985

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/6749880

values:
nofollow
external text
//doi.org/10.1210%2Fjcem-55-5-910

values:
nofollow
external text
//www.worldcat.org/issn/1478-3975

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22535698

values:
nofollow
external text
//doi.org/10.1098%2Frsif.2012.0244

values:
nofollow
external text
//www.worldcat.org/issn/1939-327X

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20299466

values:
nofollow
external text
//doi.org/10.2337%2Fdb09-0745

values:
nofollow
external text
//doi.org/10.1038%2Fsrep20345

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1936601

values:
nofollow
external text
//doi.org/10.2337%2Fdiabetes.40.11.1397

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1991575

values:
nofollow
external text
//doi.org/10.2337%2Fdiabetes.40.2.280

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1317665

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/3303333

values:
nofollow
external text
//doi.org/10.1126%2Fscience.3303333

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11122713

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18710604

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15630029

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15939062

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/10429340

values:
nofollow
external text
//doi.org/10.3402%2Fijch.v64i4.18017

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15910615

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9357799

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8675698

values:
nofollow
external text
//doi.org/10.1172%2FJCI118742

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1117841

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/10525047

values:
nofollow
external text
//doi.org/10.1172%2FJCI6572

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15723702

values:
nofollow
external text
//doi.org/10.1186%2F1743-7075-2-5

values:
nofollow
external text
//doi.org/10.1161%2F01.HYP.10.5.512

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9361681

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11082210

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17158434

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/14747241

values:
nofollow
external text
//doi.org/10.2337%2Fdiacare.27.2.538

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11723062

values:
nofollow
external text
//doi.org/10.2337%2Fdiabetes.50.12.2786

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18703413

values:
nofollow
external text
//doi.org/10.1152%2Fajpregu.00195.2008

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12663565

values:
nofollow
external text
//doi.org/10.2337%2Fdiacare.26.4.1008

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16166564

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17570985

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17065354

values:
nofollow
external text
//doi.org/10.2337%2Fdb06-0714

values: The Journal of Clinical Endocrinology and Metabolism

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11344213

values:
nofollow
external text
//doi.org/10.1210%2Fjc.86.5.2099

values: Category:CS1 maint: Multiple names: authors list

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16818461

values:
nofollow
external text
//doi.org/10.1136%2Fard.2006.058222

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/6279131

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19825820

values:
nofollow
external text
//doi.org/10.2337%2Fdc09-1321

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8288709

values:
nofollow
external text
//doi.org/10.1210%2Fjc.78.1.25

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15113720

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9368278

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9496984

values:
nofollow
external text
//doi.org/10.1001%2Fjama.279.9.669

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/2052059

values:
nofollow
external text
//doi.org/10.1056%2FNEJM199107183250302

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1681160

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16319806

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17130651

values:
nofollow
external text
//doi.org/10.2337%2Fdb06-S002

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11679437

values:
nofollow
external text
//doi.org/10.2337%2Fdiabetes.50.11.2579

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17519317

values:
nofollow
external text
//doi.org/10.1210%2Fjc.2006-2384

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15769987

values:
nofollow
external text
//doi.org/10.1210%2Fjc.2004-1959

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16430716

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19022225

values:
nofollow
external text
//doi.org/10.1016%2Fj.bcp.2008.10.020

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17426391

values:
nofollow
external text
//doi.org/10.1159%2F000101694

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17983584

values:
nofollow
external text
//doi.org/10.1016%2Fj.cmet.2007.09.011

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23954791

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19805130

values:
nofollow
external text
//doi.org/10.1073%2Fpnas.0902380106

values:
nofollow
external text
//doi.org/10.1016%2Fj.soard.2011.03.010

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19171332

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/14679095

values:
nofollow
external text
//doi.org/10.1196%2Fannals.1288.062

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11756317

values:
nofollow
external text
//doi.org/10.2337%2Fdiabetes.51.1.7

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8421683

values:
nofollow
external text
//doi.org/10.1073%2Fpnas.90.2.512

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11906177

values:
nofollow
external text
//doi.org/10.1006%2Fbbrc.2002.6654

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20724796

values:
nofollow
external text
//doi.org/10.1507%2Fendocrj.K10E-138

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21476962

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17183659

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/382871

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17957034

values:
nofollow
external text
//doi.org/10.1152%2Fajpendo.00645.2007

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15161807

values:
nofollow
external text
//doi.org/10.2337%2Fdiacare.27.6.1487

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15767618

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12679422

values:
nofollow
external text
//doi.org/10.1210%2Fjc.2002-020542

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11832527

values:
nofollow
external text
//doi.org/10.1056%2FNEJMoa012512

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22232097

values:
nofollow
external text
//doi.org/10.1377%2Fhlthaff.2011.1075

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20044472

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/25770258

values:
nofollow
external text
//doi.org/10.3945%2Fan.114.007419

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8598543

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/7782895

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8632213

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12643169

values:
nofollow
external text
//doi.org/10.1007%2Fs11892-002-0098-y

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15169967

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/8781757

values:
nofollow
external text
//doi.org/10.1007%2FBF00418533

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15460168

values:
nofollow
external text
//doi.org/10.1051%2Frnd%3A2004033

values:
nofollow
external text
//doi.org/10.1007%2FBF01736348

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20880166

values: -moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16011472

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11277552

values: ICD-10 Chapter IV: Endocrine, nutritional and metabolic diseases

values: List of ICD-9 codes 240–279: endocrine, nutritional and metabolic diseases, and immunity disorders

values: List of people with diabetes mellitus type 1

values: nowraplinks collapsible autocollapse navbox-inner

values:
/wiki/Glucose_metabolism_disorder
mw-redirect
Glucose metabolism disorder

values:
/wiki/Neurogenic_diabetes_insipidus
mw-redirect
Neurogenic diabetes insipidus

values:
/wiki/Hypothalamic_hamartoma
mw-redirect
Hypothalamic hamartoma

values: Syndrome of inappropriate antidiuretic hormone

values:
/wiki/Luteinizing_hormone_insensitivity
mw-redirect
Luteinizing hormone insensitivity

values:
/wiki/Lymphocytic_hypophysitis
mw-redirect
Lymphocytic hypophysitis

values:
/wiki/Toxic_nodular_goitre
mw-redirect
Toxic nodular goitre

values:
/wiki/Toxic_multinodular_goiter
mw-redirect
Toxic multinodular goiter

values:
/wiki/Conn_syndrome
mw-redirect
Conn syndrome

values: Apparent mineralocorticoid excess syndrome

values: Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency

values:
/wiki/Sex_hormone
mw-redirect
Sex hormone

values: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency

values: Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency

values:
/wiki/Waterhouse-Friderichsen_syndrome
mw-redirect
Waterhouse-Friderichsen syndrome

values: Congenital adrenal hyperplasia due to 3 beta-hydroxysteroid dehydrogenase deficiency

values:
/wiki/Gonadal_disorder
mw-redirect
Gonadal disorder

values:
/wiki/5%CE%B1-reductase_deficiency
mw-redirect
5α-reductase deficiency

values: Autoimmune polyendocrine syndrome multiple (page does not exist)

values: Autoimmune polyendocrine syndrome type 1

values: Autoimmune polyendocrine syndrome type 2

values: nowraplinks collapsible collapsed navbox-inner

values: Category:CS1 Italian-language sources (it)

values: Category:Articles needing additional medical references from October 2015

values: Category:All articles needing additional references

values: Category:All articles with unsourced statements

values: Category:Articles with unsourced statements from October 2010

values: Discussion about edits from this IP address [ctrl-alt-n]

values: A list of edits made from this IP address [ctrl-alt-y]

values: You are encouraged to create an account and log in; however, it is not mandatory

values: You're encouraged to log in; however, it's not mandatory. [ctrl-alt-o]

values:
/wiki/Insulin_resistance
View the content page [ctrl-alt-c]
c

values: Discussion about the content page [ctrl-alt-t]

values: p-namespaces navigation vectorTabs p-namespaces-label

values:
p-variants
navigation
vectorMenu emptyPortlet
p-variants-label

values: Past revisions of this page [ctrl-alt-h]

values: p-views navigation vectorTabs p-views-label

values:
p-cactions
navigation
vectorMenu emptyPortlet
p-cactions-label

values:
mw-wiki-logo
/wiki/Main_Page
Visit the main page

values:
/wiki/Main_Page
Visit the main page [ctrl-alt-z]
z

values: Featured content – the best of Wikipedia

values: Find background information on current events

values:
/wiki/Special:Random
Load a random article [ctrl-alt-x]
x

values: portal navigation p-navigation p-navigation-label

values: Guidance on how to use and edit Wikipedia

values: About the project, what you can do, where to find things

values: A list of recent changes in the wiki [ctrl-alt-r]

values: portal navigation p-interaction p-interaction-label

values: List of all English Wikipedia pages containing links to this page [ctrl-alt-j]

values: Recent changes in pages linked from this page [ctrl-alt-k]

values:
/wiki/Wikipedia:File_Upload_Wizard
Upload files [ctrl-alt-u]
u

values: A list of all special pages [ctrl-alt-q]

values: Permanent link to this revision of the page

values: Link to connected data repository item [ctrl-alt-g]

values: Printable version of this page [ctrl-alt-p]

values: portal navigation p-wikibase-otherprojects p-wikibase-otherprojects-label

values:
uls-settings-trigger
Language settings
0
button
true

values: مقاومة الإنسولين – Arabic

values: Инсулинова резистентност – Bulgarian

values: مقاومت به انسولین – Persian

values: 인슐린 저항성 – Korean

values: インスリン抵抗性 – Japanese

values: Инсулинорезистентность – Russian

values: mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Insulin_resistance rootpage-Insulin_resistance vector-experimental-print-styles vector-nav-directionality skin-vector action-view